Currently, evexomostat is being investigated in two phase 1b/2 clinical proof-of-concept studies: in second-line metastatic HR+/Her2− breast cancer in combination with either the PI3Kα inhibitor alpelisib or the AKT inhibitor capivasertib plus fulvestrant (the Amelia-1 study – www.amelia1.com) and, in collaboration with Memorial Sloan Kettering Cancer Center, in first- to third-line metastatic triple-negative breast cancer in combination with eribulin in women with baseline metabolic dysfunction (the Aretha study – www.aretha1.com). Here, AKT1 is linked to triple-negative breast carcinoma.